Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 5Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Colorectal Neoplasms 2Adenocarcinoma 2Rectal Neoplasms 1Rectal Diseases 1Metastatic Adenocarcinoma of the Pancreas 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 25Cisplatin 9Paclitaxel 6Fluorouracil 5Carboplatin 4Saline Solution 3Capecitabine 3Bevacizumab 3Oxaliplatin 2Gemcitabine 2Docetaxel 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2lenvatinib 1Trastuzumab 1S 1 (combination) 1Irinotecan 1IFL protocol 1Glucose 1Doxorubicin 1Brentuximab Vedotin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Oxaliplatin × Clear all
NCT03675737 2026-02-27

KEYNOTE-859

Merck Sharp & Dohme LLC

Phase 3 Completed
1,579 enrolled 31 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Merck Sharp & Dohme LLC

Phase 3 Completed
738 enrolled 22 charts 3 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡